Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 239

1.

Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management.

Barbier F, Andremont A, Wolff M, Bouadma L.

Curr Opin Pulm Med. 2013 May;19(3):216-28. doi: 10.1097/MCP.0b013e32835f27be. Review.

PMID:
23524477
2.
3.

Management of ventilator-associated pneumonia: epidemiology, diagnosis and antimicrobial therapy.

Bassetti M, Taramasso L, Giacobbe DR, Pelosi P.

Expert Rev Anti Infect Ther. 2012 May;10(5):585-96. doi: 10.1586/eri.12.36. Review.

PMID:
22702322
4.

High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia.

Chung DR, Song JH, Kim SH, Thamlikitkul V, Huang SG, Wang H, So TM, Yasin RM, Hsueh PR, Carlos CC, Hsu LY, Buntaran L, Lalitha MK, Kim MJ, Choi JY, Kim SI, Ko KS, Kang CI, Peck KR; Asian Network for Surveillance of Resistant Pathogens Study Group.

Am J Respir Crit Care Med. 2011 Dec 15;184(12):1409-17. doi: 10.1164/rccm.201102-0349OC. Epub 2011 Sep 15.

PMID:
21920919
5.

Causative agents and resistance among hospital-acquired and ventilator-associated pneumonia patients at Srinagarind Hospital, northeastern Thailand.

Reechaipichitkul W, Phondongnok S, Bourpoern J, Chaimanee P.

Southeast Asian J Trop Med Public Health. 2013 May;44(3):490-502.

PMID:
24050082
6.

[Guidelines for treatment of pneumonia in intensive care units].

Emmi V.

Infez Med. 2005;Suppl:7-17. Review. Italian.

7.

Differences in hospital- and ventilator-associated pneumonia due to Staphylococcus aureus (methicillin-susceptible and methicillin-resistant) between Europe and Latin America: a comparison of the EUVAP and LATINVAP study cohorts.

Rello J, Molano D, Villabon M, Reina R, Rita-Quispe R, Previgliano I, Afonso E, Restrepo MI; LATINVAP and EUVAP Study Investigators.

Med Intensiva. 2013 May;37(4):241-7. doi: 10.1016/j.medin.2012.04.008. Epub 2012 Jun 28.

8.

Ventilator-associated pneumonia.

Bassi GL, Ferrer M, Marti JD, Comaru T, Torres A.

Semin Respir Crit Care Med. 2014 Aug;35(4):469-81. doi: 10.1055/s-0034-1384752. Epub 2014 Aug 11. Review.

PMID:
25111643
9.

Treatment of methicillin-resistant Staphylococcus aureus ventilator-associated pneumonia with high-dose vancomycin or linezolid.

Hamilton LA, Christopher Wood G, Magnotti LJ, Croce MA, Martin JB, Swanson JM, Boucher BA, Fabian TC.

J Trauma Acute Care Surg. 2012 Jun;72(6):1478-83. doi: 10.1097/TA.0b013e318250911b.

PMID:
22695410
10.

[Adult hospital acquired pneumonia: a multicenter study on microbiology and clinical characteristics of patients from 9 Chinese cities].

Liu YN, Cao B, Wang H, Chen LA, She DY, Zhao TM, Liang ZX, Sun TY, Li YM, Tong ZH, Wang Z, He B, Yang W, Qu JM, Li XY, Chen RC, Ye F, Kang J, Li ER, Chen P, Zheng Y, Ma ZS, Ren J, Shi Y, Sun WK, Feng YL, Fan H, Jiang SJ, Zhang S, Xiong SD, Zuo P, Wang ZW.

Zhonghua Jie He He Hu Xi Za Zhi. 2012 Oct;35(10):739-46. Chinese.

PMID:
23289990
11.

Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults.

Pugh R, Grant C, Cooke RP, Dempsey G.

Cochrane Database Syst Rev. 2015 Aug 24;(8):CD007577. doi: 10.1002/14651858.CD007577.pub3. Review.

PMID:
26301604
12.

Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia.

Rello J, Ulldemolins M, Lisboa T, Koulenti D, Mañez R, Martin-Loeches I, De Waele JJ, Putensen C, Guven M, Deja M, Diaz E; EU-VAP/CAP Study Group.

Eur Respir J. 2011 Jun;37(6):1332-9. doi: 10.1183/09031936.00093010. Epub 2010 Sep 16.

13.

Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia.

Haque NZ, Zuniga LC, Peyrani P, Reyes K, Lamerato L, Moore CL, Patel S, Allen M, Peterson E, Wiemken T, Cano E, Mangino JE, Kett DH, Ramirez JA, Zervos MJ; Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Investigators.

Chest. 2010 Dec;138(6):1356-62. doi: 10.1378/chest.09-2453. Epub 2010 Jun 17.

PMID:
20558550
14.

Curbing resistance development: maximizing the utility of available agents.

Burgess DS.

J Manag Care Pharm. 2009 Jun;15(5 Suppl):S5-9. Review.

PMID:
19505173
15.

Antibiotic resistance in nosocomial respiratory infections.

Denys GA, Relich RF.

Clin Lab Med. 2014 Jun;34(2):257-70. doi: 10.1016/j.cll.2014.02.004. Epub 2014 Apr 13. Review.

PMID:
24856527
17.

Nosocomial ventilator-associated pneumonia in Cuban intensive care units: bacterial species and antibiotic resistance.

Medell M, Hart M, Duquesne A, Espinosa F, Valdés R.

MEDICC Rev. 2013 Apr;15(2):26-9.

18.

Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia.

Kaye KS, Udeani G, Cole P, Friedland HD.

Hosp Pract (1995). 2015;43(3):144-9. doi: 10.1080/21548331.2015.1037228. Epub 2015 May 8.

PMID:
25956849
19.

Molecular diagnosis in HAP/VAP.

Lung M, Codina G.

Curr Opin Crit Care. 2012 Oct;18(5):487-94. doi: 10.1097/MCC.0b013e3283577d37. Review.

PMID:
22889869
20.

Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study.

Michalopoulos A, Fotakis D, Virtzili S, Vletsas C, Raftopoulou S, Mastora Z, Falagas ME.

Respir Med. 2008 Mar;102(3):407-12. Epub 2007 Dec 3.

Supplemental Content

Support Center